Primera Therapeutics
Pioneering TALE‑based mtDNA editing to cure mitochondrial diseases, starting with kidney disease.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
Pioneering TALE‑based mtDNA editing to cure mitochondrial diseases, starting with kidney disease.
Mitochondrial diseaseKidney diseaseMetabolic disordersCNS disordersMusculoskeletal disorders
Technology Platform
Customizable TALE‑based mitochondrial DNA editing system that precisely corrects pathogenic mtDNA mutations in patient‑derived cells.
Opportunities
First‑in‑class mtDNA editing platform enables a multi‑indication pipeline across rare mitochondrial diseases and common metabolic disorders.
Risk Factors
Regulatory uncertainty for mitochondrial genome editing and potential safety concerns of ex vivo edited cell therapies.
Competitive Landscape
Few companies target mitochondrial DNA directly; Primera’s TALE platform differentiates from CRISPR‑based approaches but must demonstrate superior efficacy and safety.